Assessing sirtuin expression in endometrial carcinoma and non-neoplastic endometrium

Bartosch, Carla; Monteiro‐Reis, Sara; Almeida-Rios, Diogo; Vieira, Renata; Castro, Armando; Moutinho, Manuel; Rodrigues, Marta; Graça, Inês; Lopes, José Manuel; Jerónimo, Carmen

doi:10.18632/oncotarget.6691

Cited by 73 publications

(49 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In comparison with normal tissues, SIRT5 was significantly under expressed in head and neck squamous cell carcinoma samples, indicating the role of SIRT5 as a tumor-suppressor (13). Similarly, the expression levels of SIRT5 were substantially downregulated in endometrial carcinoma tissues compared with non-neoplastic endometrium (11). However, no significant change in SIRT5 expression was observed in basal cell carcinoma tissues relative to non-cancerous tissues (12).…”

Section: Discussionmentioning

confidence: 93%

“…In recent years, studies have evaluated the potential roles of SIRTs in different cancer types (8)(9)(10). In particular, the expression of SIRT5 has been assessed in various types of cancer, including endometrial carcinoma, head and neck squamous cell carcinoma, basal cell carcinoma, lung and breast cancer (11)(12)(13)(14). However, to the best of our knowledge, no study has investigated the value of SIRT5 in predicting the pCR of TNBC patients to NAC, or the potential association of SIRT5 expression with the clinicopathological characteristics and prognosis of breast cancer patients.…”

Section: Sirt5 As a Biomarker For Response To Anthracycline-taxane-bamentioning

confidence: 99%

See 1 more Smart Citation

SIRT5 as a biomarker for response to anthracycline-taxane-based neoadjuvant chemotherapy in triple-negative breast cancer

Che

Song

et al. 2018

Oncol Rep

View full text Add to dashboard Cite

Neoadjuvant chemotherapy (NAC) is of great importance for patients with triple-negative breast cancer (TNBC) and the achievement of pathological complete response (pCR) to NAC in TNBC patients indicates survival benefits. However, the identification of reliable predictive biomarkers of pCR to NAC in TNBC patients remains an urgent and largely unattended medical issue. In the present study, we evaluated the differentially expressed genes (DEGs) between pCR and non-pCR patients after doxorubicin/cyclophosphamide therapy, followed by paclitaxel pre-operative treatment in 64 TNBC patients recorded in the GSE41998 dataset of Gene Expression Omnibus and identified 118 DEGs. Subsequently, we selected five core genes that were closely associated with the pCR of TNBC patients by using a genetic algorithm‑support vector machine-based method. Sirtuin 5 (SIRT5) was one of the five core genes and patients who achieved pCR expressed higher levels of SIRT5. Thus, we speculated that SIRT5 may be a potential predictive marker of the response to anthracycline-taxane-based chemotherapy. Oncomine analysis revealed that the expression levels of SIRT5 were higher in epirubicin/cyclophosphamide-docetaxel responders compared with non-responders. Furthermore, Gene Ontology analysis indicated that SIRT5 may affect the response to anthracycline-taxane-based chemotherapy by regulating the Rho pathway. It was also observed that SIRT5 was upregulated in TNBC and breast cancer with BRCA1 mutation subtypes. High SIRT5 expression was also associated with poor clinical outcomes of breast cancer patients. In conclusion, the present study revealed SIRT5 as a biomarker for response to anthracycline-taxane-based NAC in patients with TNBC and identified a series of novel biological functions of SIRT5 in breast cancer.

show abstract

Section: Discussionmentioning

confidence: 93%

Section: Sirt5 As a Biomarker For Response To Anthracycline-taxane-bamentioning

confidence: 99%

SIRT5 as a biomarker for response to anthracycline-taxane-based neoadjuvant chemotherapy in triple-negative breast cancer

Che

Song

et al. 2018

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…In support of this notion, SIRT5 is overexpressed in non-small cell lung cancer [149] and ovarian carcinoma [150]. In accord with other sirtuins, SIRT5 is also emerged as a tumor suppressor in squamous cell carcinoma [151] and endometrial carcinoma [152]. …”

Section: Sirtuins In Metabolismmentioning

confidence: 99%

Sirtuins in metabolism, DNA repair and cancer

Mei

Zhang

et al. 2016

J Exp Clin Cancer Res

129

View full text Add to dashboard Cite

The mammalian sirtuin family has attracted tremendous attention over the past few years as stress adaptors and post-translational modifier. They have involved in diverse cellular processes including DNA repair, energy metabolism, and tumorigenesis. Notably, genomic instability and metabolic reprogramming are two of characteristic hallmarks in cancer. In this review, we summarize current knowledge on the functions of sirtuins mainly regarding DNA repair and energy metabolism, and further discuss the implication of sirtuins in cancer specifically by regulating genome integrity and cancer-related metabolism.

show abstract

“…There are 7 members in the family: SIRT1-SIRT7. Many of these proteins have been reported to regulate important pathways and are responsible for vital biological process (8)(9)(10). SIRT6, like the other members in the family, also exhibits many pivotal functions and multiple enzymatic activities (11)(12)(13).…”

Section: Introductionmentioning

confidence: 99%

SIRT6 is upregulated and associated with cancer aggressiveness in papillary thyroid cancer via BRAF/ERK/Mcl-1 pathway

Liu

et al. 2017

International Journal of Oncology

View full text Add to dashboard Cite

Sirtuin 6 (SIRT6) is a member of the SIRT family NAD+‑dependent deacetylases reported to function in controlling organism homeostasis, lifespan, and diseases. This study investigated the role of SIRT6 in papillary thyroid cancer (PTC). Data of 391 PTC patients was extracted from The Cancer Genome Atlas database to investigate the expression of SIRTs (SIRT1‑7) and their relationship with clinicopathological parameters. Additional 45 pairs of PTC tumor tissues and corresponding non‑tumor tissues were studied using microarray analysis for SIRT6 expression. Surgically resected, pathologically diagnosed tissues from 130 in‑house PTC patients were used for confirmation of SIRT6 expression. SIRT6 silenced K1 and TPC‑1 cells were generated to explore the influence of SIRT6 on cancer cell aggressiveness in vitro. SIRT6 mRNA and protein levels were upregulated in PTC tumor tissues and its overexpression was an independent biomarker for nodal metastasis (odds ratio=1.794, 95% confidence interval: 1.256‑1.920, p=0.012). SIRT6 expression was related to poor recurrence‑free survival, however, not significantly. Silencing SIRT6 downregulated PTC cell aggressiveness in vitro by suppressing ERK and Mcl‑1. In conclusion, these results suggest that SIRT6 enhances cell aggressiveness in PTC via BRAF/ERK/Mcl‑1 pathway, and thus may be a promising target in the treatment of the disease.

show abstract

Assessing sirtuin expression in endometrial carcinoma and non-neoplastic endometrium

Cited by 73 publications

References 30 publications

SIRT5 as a biomarker for response to anthracycline-taxane-based neoadjuvant chemotherapy in triple-negative breast cancer

SIRT5 as a biomarker for response to anthracycline-taxane-based neoadjuvant chemotherapy in triple-negative breast cancer

Sirtuins in metabolism, DNA repair and cancer

SIRT6 is upregulated and associated with cancer aggressiveness in papillary thyroid cancer via BRAF/ERK/Mcl-1 pathway

Contact Info

Product

Resources

About